Sjoerd A.M.E.G. Timmermans

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar, Sanne de Bruin, Matthias H. Busch et al. · The Lancet Rheumatology · 2020 · 198 citations · Full text

Clinical Infectious Disease, Covid-19 Pandemic, Immunology +7

Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities

Sjoerd A.M.E.G. Timmermans, Myrurgia A. Abdul‐Hamid, Joris Vanderlocht et al. · Kidney International · 2017 · 141 citations · Full text

Thrombosis, Hypertension, Vascular Disease +9

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 131 citations · Full text

Critical Care Medicine, Clinical Infectious Disease, Anti-c5a Antibody +6

C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension

Sjoerd A.M.E.G. Timmermans, Myrurgia A. Abdul‐Hamid, Judith Potjewijd et al. · Journal of the American Society of Nephrology · 2018 · 95 citations · Full text

Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy

Sjoerd A.M.E.G. Timmermans, Myrurgia Abdul Hamid, Jan Willem Cohen Tervaert et al. · American Journal of Nephrology · 2015 · 71 citations · Full text